Wasatch Advisors LP Buys 28,161 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Wasatch Advisors LP grew its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 3.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 936,842 shares of the company's stock after acquiring an additional 28,161 shares during the quarter. Medpace accounts for approximately 1.5% of Wasatch Advisors LP's investment portfolio, making the stock its 15th largest position. Wasatch Advisors LP owned 3.01% of Medpace worth $311,247,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. R Squared Ltd acquired a new position in Medpace during the 4th quarter worth approximately $30,000. SBI Securities Co. Ltd. acquired a new position in shares of Medpace during the fourth quarter worth $31,000. Jones Financial Companies Lllp increased its holdings in shares of Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after buying an additional 110 shares in the last quarter. Lindbrook Capital LLC lifted its stake in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after acquiring an additional 29 shares during the last quarter. Finally, Assetmark Inc. boosted its holdings in shares of Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after acquiring an additional 29 shares in the last quarter. Institutional investors own 77.98% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. TD Cowen downgraded Medpace from a "buy" rating to a "hold" rating and dropped their target price for the company from $370.00 to $328.00 in a research report on Monday, April 14th. Robert W. Baird raised their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Mizuho reduced their target price on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Truist Financial dropped their price target on shares of Medpace from $347.00 to $333.00 and set a "hold" rating for the company in a research note on Thursday, April 10th. Finally, Leerink Partners began coverage on shares of Medpace in a research note on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective on the stock. Ten analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Medpace presently has a consensus rating of "Hold" and an average price target of $357.50.

Medpace Stock Performance

Shares of NASDAQ:MEDP traded down $0.22 during midday trading on Friday, reaching $296.28. The company's stock had a trading volume of 698,291 shares, compared to its average volume of 325,831. The firm has a 50 day moving average price of $318.52 and a two-hundred day moving average price of $333.31. Medpace Holdings, Inc. has a fifty-two week low of $272.00 and a fifty-two week high of $459.77. The firm has a market capitalization of $8.96 billion, a price-to-earnings ratio of 23.46, a PEG ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.